Should I buy or sell HLS Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares. View HLS analyst ratings or view top-rated stocks .

What is HLS Therapeutics' stock price target for 2024?

3 brokerages have issued 1-year price targets for HLS Therapeutics' shares. Their HLS share price targets range from C$5.00 to C$17.50. On average, they predict the company's share price to reach C$10.50 in the next twelve months. This suggests a possible upside of 188.5% from the stock's current price. View analysts price targets for HLS or view top-rated stocks among Wall Street analysts .

How have HLS shares performed in 2023?

HLS Therapeutics' stock was trading at C$9.83 on January 1st, 2023. Since then, HLS stock has decreased by 63.0% and is now trading at C$3.64. View the best growth stocks for 2023 here .

When is HLS Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our HLS earnings forecast .

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc. (TSE:HLS) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.12. The company earned $21.52 million during the quarter, compared to the consensus estimate of $21.97 million. HLS Therapeutics had a negative net margin of 45.41% and a negative trailing twelve-month return on equity of 24.49%.

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?

HLS Therapeutics declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 5.49%. The ex-dividend date is Thursday, April 27th. Read our dividend analysis for HLS .

Is HLS Therapeutics a good dividend stock?

HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 5.56%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for HLS .

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT) , Fairfax Financial (FFH) , Fortis (FTS) , Aurora Cannabis (ACB) , Aphria (APHA) , Alimentation Couche-Tard (ATD.B) , BlackBerry (BB) , BCE (BCE) , Bank of Montreal (BMO) and Bank of Nova Scotia (BNS) .

How do I buy shares of HLS Therapeutics?

Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

HLS Therapeutics Stock Price, News & Analysis (TSE:HLS)

C$3.64

+0.04 (+1.11%)

(As of 12/8/2023 ET)

Compare

Today's Range: C$3.64
▼
C$3.76
50-Day Range: C$3.36
▼
C$5.26
52-Week Range: C$3.34
▼
C$11.22

Volume: 3,831 shs
Average Volume: 22,212 shs
Market Capitalization: C$116.73 million

P/E Ratio: N/A
Dividend Yield: 5.49%
Price Target: C$10.50

Stock Analysis Analyst Forecasts Chart Competitors Dividend Earnings Headlines Insider Trades

About HLS Therapeutics Stock (TSE:HLS)

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

HLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLS Stock News Headlines

November 15, 2023 | finance.yahoo.com

Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates

November 14, 2023 | finance.yahoo.com

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 9, 2023 | marketwatch.com

HLS Therapeutics Plans to Buyback Up to 5% of Its Shares

November 9, 2023 | finance.yahoo.com

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

November 9, 2023 | markets.businessinsider.com

HLS Therapeutics earnings preview: what Wall Street is expecting

October 2, 2023 | finance.yahoo.com

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

September 7, 2023 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy HLS Therapeutics Stock

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

August 26, 2023 | seekingalpha.com

HLTRF HLS Therapeutics Inc.

August 23, 2023 | theglobeandmail.com

HLS Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (HLS)

August 13, 2023 | markets.businessinsider.com

Bloom Burton Remains a Buy on HLS Therapeutics Inc (HLS)

August 3, 2023 | finance.yahoo.com

HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call

August 3, 2023 | msn.com

HLS Therapeutics (HLTRF) Price Target Decreased by 12.21% to 11.36

July 28, 2023 | markets.businessinsider.com

HLS Therapeutics Inc (HLS) Gets a Hold Rating from Raymond James

July 28, 2023 | finance.yahoo.com

With 38% ownership, HLS Therapeutics Inc. (TSE:HLS) has piqued the interest of hedge funds investors

July 10, 2023 | markets.businessinsider.com

Stifel Nicolaus Remains a Buy on HLS Therapeutics Inc (HLS)

July 6, 2023 | fool.com

Hls Therapeutics (TSX: HLS)

July 1, 2023 | finance.yahoo.com

Athyrium Capital Announces Sale of Shares of HLS Therapeutics

June 22, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on HLS Therapeutics Inc (HLS)

June 22, 2023 | marketwatch.com

HLS Therapeutics Names John Welborn Chairman, Adds Polar Asset Management Candidate to Board

June 22, 2023 | finance.yahoo.com

HLS Therapeutics Announces Updates to its Board of Directors

June 19, 2023 | markets.businessinsider.com

HLS Therapeutics Inc (HLS) Received its Third Buy in a Row

June 8, 2023 | finance.yahoo.com

HLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of Directors

June 8, 2023 | markets.businessinsider.com

Stifel Nicolaus Thinks HLS Therapeutics Inc’s Stock is Going to Recover

May 25, 2023 | baystreet.ca

This Healthcare Stock Just Hit a 52-Week Low: Is it Time to Buy?

May 16, 2023 | theglobeandmail.com

Closing Bell: Hls Therapeutics Inc flat on Tuesday (HLS)

See More Headlines

Receive HLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/09/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:HLS
CUSIP: N/A
CIK: N/A
Web: www.hlstherapeutics.com
Phone: 647-495-9000
Fax: N/A
Employees: 99
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$10.50
High Stock Price Target: C$17.50
Low Stock Price Target: C$5.00
Potential Upside/Downside: +188.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($1.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-28,560,000.00
Net Margins: -45.41%
Pretax Margin: N/A
Return on Equity: -24.49%
Return on Assets: -3.58%

Debt

Debt-to-Equity Ratio: 89.13
Current Ratio: 1.72
Quick Ratio: 1.01

Sales & Book Value

Annual Sales: C$62.89 million
Price / Sales: 1.86
Cash Flow: C$0.24 per share
Price / Cash Flow: 15.22
Book Value: C$3.17 per share
Price / Book: 1.15

Miscellaneous

Outstanding Shares: 32,070,000
Free Float: N/A
Market Cap: C$116.73 million
Optionable: Not Optionable
Beta: 1.05

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Tim Hendrickson M.B.A. (Age 51)
Chief Financial Officer
Comp: $524.49k
Dr. Jason A. Gross Pharm.D. (Age 58)
Vice President of Scientific Affairs
Comp: $351.75k
Mr. Ryan C. Lennox B.A. (Age 42)
J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary
Comp: $386.6k
Mr. Craig Stuart Millian M.B.A. (Age 55)
CEO & Director
Brian T. Walsh
Senior Vice President of Commercial
Mr. David Spence (Age 55)
VP & Corporate Controller

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

HLS Stock Analysis - Frequently Asked Questions

Should I buy or sell HLS Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares.
View HLS analyst ratings or view top-rated stocks.
What is HLS Therapeutics' stock price target for 2024?: 3 brokerages have issued 1-year price targets for HLS Therapeutics' shares. Their HLS share price targets range from C$5.00 to C$17.50. On average, they predict the company's share price to reach C$10.50 in the next twelve months. This suggests a possible upside of 188.5% from the stock's current price.
View analysts price targets for HLS or view top-rated stocks among Wall Street analysts.
How have HLS shares performed in 2023?: HLS Therapeutics' stock was trading at C$9.83 on January 1st, 2023. Since then, HLS stock has decreased by 63.0% and is now trading at C$3.64.
View the best growth stocks for 2023 here.
When is HLS Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our HLS earnings forecast.
How were HLS Therapeutics' earnings last quarter?: HLS Therapeutics Inc. (TSE:HLS) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.12. The company earned $21.52 million during the quarter, compared to the consensus estimate of $21.97 million. HLS Therapeutics had a negative net margin of 45.41% and a negative trailing twelve-month return on equity of 24.49%.

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?: HLS Therapeutics declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 5.49%. The ex-dividend date is Thursday, April 27th.
Read our dividend analysis for HLS.
Is HLS Therapeutics a good dividend stock?: HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 5.56%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for HLS.
What other stocks do shareholders of HLS Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS).
How do I buy shares of HLS Therapeutics?: Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:HLS) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial